A Phase I safety study and a Phase II ulcerative colitis trial of the BPC-157 formulation PL 14736 were conducted by the Croatian pharmaceutical company Pliva, but full peer-reviewed Phase II efficacy results have not been published
Panel member Elizabeth Rebello, a pharmacist and anesthesiologist, told the committee that she voted no on BPC-157 because of the lack of efficacy data and safety concerns
Sheena H
In this blog, well explore the uses, benefits, and importance of Vitamin B12 injection therapy while exploring its role in promoting energy, health, and vitality
[1] Contamination risks, potency variations, and sterility concerns represent significant potential hazards with compounded injectable medications
But I think theyre just saying the same thing